AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 231 min read$CORT

CORCEPT THERAPEUTICS INC (CORT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Announces Planned Leadership Transition Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif. – September 23, 2026 – C

Original reporting
SEC EDGAR 8-K
Published Sep 23, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CORTNeutralMed
01

Why it matters

The filing provides the first public disclosure of the executive change, offering a fresh data point for investors.

02

Market read

Executive turnover is a standard corporate update; likely limited price effect unless execution deviates from expectations.

03

What to watch

Maduck remains as senior advisor, providing continuity; Gunn's Gilead background may bring new sales strategies.

Relevance 6/10Novelty 6/10Timing: effective Oct 1

Background

Corcept Therapeutics (NASDAQ:CORT) filed an 8‑K announcing a planned leadership transition in its Endocrinology division.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

SEC 8‑K reports retirement of President Sean Maduck and appointment of Justin Gunn as new President of the Endocrinology division, effective Oct 1.

Expected impact

minimal short‑term impact; market may price in transition gradually.

Evidence & confidence

Executive changes are disclosed for the first time; no immediate financial metrics or strategic shift disclosed.

Market effects

Sector

May signal continuity in Corcept's cortisol‑modulation pipeline, but no sector‑wide impact.

Regional

Limited to US biotech investors tracking Corcept.

Global

Low; only relevant to shareholders of CORT.

Counterpoint

What could challenge this read

The appointment could accelerate commercialization of Lifyorli, offering upside if execution exceeds expectations.

Key entities

  • executive
    Sean Maduck

    Retiring President of Endocrinology division, will stay as senior commercial advisor.

  • executive
    Justin Gunn

    New President of Endocrinology division, previously VP of Sales for Oncology.

Read at source← All news

Related articles

SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min
SEP 19
$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min
SEP 18
$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min
AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min